HYPERLIPIDEMIA IN CHILDHOOD NEPHROTIC SYNDROME

被引:21
|
作者
THABET, MAEH [1 ]
SALCEDO, JR [1 ]
CHAN, JCM [1 ]
机构
[1] VIRGINIA COMMONWEALTH UNIV,MED COLL VIRGINIA,CHILDRENS MED CTR,DEPT PEDIAT,DIV NEPHROL,MCV STN,RICHMOND,VA 23298
关键词
NEPHROTIC SYNDROME; HYPERLIPIDEMIA; ATHEROSCLEROSIS; GLOMERULOSCLEROSIS;
D O I
暂无
中图分类号
R72 [儿科学];
学科分类号
100202 ;
摘要
Hyperlipidemia is an important characteristic of nephrotic syndrome (NS). Elevation of plasma total cholesterol, or more specifically low-density lipoprotein cholesterol, is the major lipid abnormality in NS, although hypertriglyceridemia may develop as the disorder progresses. The pathophysiology of nephrotic hyperlipidemia is complex. The prevailing view is that both hepatic synthesis of lipids and of apolipoproteins is increased, and that the clearance of chylomicrons and very low-density lipoproteins is reduced. The precise contribution of increased lipogenesis and decreased lipid catabolism to hyperlipidemia, and their relationship to urinary protein loss, hypoalbuminemia and reduced serum oncotic pressure remain controversial. There are two potential risks of elevated plasma lipids: atherosclerosis and progression of glomerular injury. Although neither of these complications has been proved with certainty, there is growing evidence that both may be long-term consequences of NS. Therefore, the diagnosis and treatment of lipid abnormalities, important aspects of the management of nephrotic children, is summarized here to provide pediatric nephrologists with an informed choice.
引用
收藏
页码:559 / 566
页数:8
相关论文
共 50 条
  • [1] PATHOGENESIS OF HYPERLIPIDEMIA IN THE NEPHROTIC SYNDROME
    ATTMAN, PO
    ALAUPOVIC, P
    AMERICAN JOURNAL OF NEPHROLOGY, 1990, 10 : 69 - 75
  • [2] Probucol for treatment of hyperlipidemia in persistent childhood nephrotic syndrome Report of a prospective uncontrolled multicenter study
    U. Querfeld
    B. Kohl
    W. Fiehn
    T. Minor
    D. Michalk
    K. Schärer
    D. E. Müller-Wiefel
    Pediatric Nephrology, 1999, 13 : 7 - 12
  • [3] Should hyperlipidemia in children with the nephrotic syndrome be treated?
    Querfeld, U
    PEDIATRIC NEPHROLOGY, 1999, 13 (01) : 77 - 84
  • [4] Probucol for treatment of hyperlipidemia in persistent childhood nephrotic syndrome -: Report of a prospective uncontrolled multicenter study
    Querfeld, U
    Kohl, B
    Fiehn, W
    Minor, T
    Michalk, D
    Schärer, K
    Müller-Wiefel, DE
    PEDIATRIC NEPHROLOGY, 1999, 13 (01) : 7 - 12
  • [5] RELATIONSHIP BETWEEN HYPERLIPIDEMIA, LIPID MEDIATORS, AND PROGRESSIVE GLOMERULOSCLEROSIS IN THE NEPHROTIC SYNDROME
    KEESFOLTS, D
    DIAMOND, JR
    AMERICAN JOURNAL OF NEPHROLOGY, 1993, 13 (05) : 365 - 375
  • [6] TREATMENT OF HYPERLIPIDEMIA IN THE NEPHROTIC SYNDROME - THE EFFECTS OF PRAVASTATIN THERAPY
    SPITALEWITZ, S
    PORUSH, JG
    CATTRAN, D
    WRIGHT, N
    AMERICAN JOURNAL OF KIDNEY DISEASES, 1993, 22 (01) : 143 - 150
  • [7] SEVERE HYPERLIPIDEMIA DUE TO MULTIPLE FACTORS IN A CHILD WITH NEPHROTIC SYNDROME
    ONGKINGCO, JRC
    MANN, WA
    RULEY, EJ
    GREGG, RE
    CHILD NEPHROLOGY AND UROLOGY, 1991, 11 (02) : 107 - 110
  • [8] Ofatumumab for the treatment of childhood nephrotic syndrome
    Wang, Chia-Shi
    Liverman, Rochelle Schmidt
    Garro, Rouba
    George, Roshan Punnoose
    Glumova, Anastacia
    Karp, Alana
    Jernigan, Stephanie
    Warshaw, Barry
    PEDIATRIC NEPHROLOGY, 2017, 32 (05) : 835 - 841
  • [9] Ofatumumab for the treatment of childhood nephrotic syndrome
    Chia-Shi Wang
    Rochelle Schmidt Liverman
    Rouba Garro
    Roshan Punnoose George
    Anastacia Glumova
    Alana Karp
    Stephanie Jernigan
    Barry Warshaw
    Pediatric Nephrology, 2017, 32 : 835 - 841
  • [10] Should hyperlipidemia in children with the nephrotic syndrome be treated?
    Uwe Querfeld
    Pediatric Nephrology, 1999, 13 : 77 - 84